Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AXGN logo AXGN
Upturn stock ratingUpturn stock rating
AXGN logo

Axogen Inc (AXGN)

Upturn stock ratingUpturn stock rating
$16.14
Last Close (24-hour delay)
Profit since last BUY19.91%
upturn advisory
Strong Buy
BUY since 28 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/29/2025: AXGN (4-star) is a STRONG-BUY. BUY since 28 days. Profits (19.91%). Updated daily EoD!

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $24.71

1 Year Target Price $24.71

Analysts Price Target For last 52 week
$24.71 Target price
52w Low $9.22
Current$16.14
52w High $21

Analysis of Past Performance

Type Stock
Historic Profit 80.17%
Avg. Invested days 35
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/29/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 746.32M USD
Price to earnings Ratio -
1Y Target Price 24.71
Price to earnings Ratio -
1Y Target Price 24.71
Volume (30-day avg) 7
Beta 0.99
52 Weeks Range 9.22 - 21.00
Updated Date 08/30/2025
52 Weeks Range 9.22 - 21.00
Updated Date 08/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.1

Earnings Date

Report Date 2025-08-05
When -
Estimate 0.06
Actual 0.12

Profitability

Profit Margin -2.29%
Operating Margin (TTM) 2.95%

Management Effectiveness

Return on Assets (TTM) 0.54%
Return on Equity (TTM) -4.48%

Valuation

Trailing PE -
Forward PE 67.11
Enterprise Value 780908944
Price to Sales(TTM) 3.67
Enterprise Value 780908944
Price to Sales(TTM) 3.67
Enterprise Value to Revenue 3.84
Enterprise Value to EBITDA 72.04
Shares Outstanding 46012600
Shares Floating 45242324
Shares Outstanding 46012600
Shares Floating 45242324
Percent Insiders 4.79
Percent Institutions 87.52

ai summary icon Upturn AI SWOT

Axogen Inc

stock logo

Company Overview

overview logo History and Background

Axogen Inc. was founded in 2002. It is a regenerative medicine company focused on developing and marketing innovative solutions for peripheral nerve repair. Its initial focus was on porcine submucosa xenografts, later expanding into nerve allografts and other nerve repair technologies.

business area logo Core Business Areas

  • Nerve Repair and Regeneration: Axogen develops, commercializes, and markets products for surgical repair of peripheral nerves, utilizing both allograft and xenograft technologies.

leadership logo Leadership and Structure

Karen Zaderej is the current Chairman, CEO, and President. The company has a typical corporate structure with departments for research, development, sales, marketing, and operations.

Top Products and Market Share

overview logo Key Offerings

  • Avance Nerve Graft: An off-the-shelf, processed human nerve allograft for bridging nerve gaps. Axogen has a significant market share in nerve allografts. Competitors include Integra LifeSciences and Stryker, though Avance is a leading brand.
  • Axoguard Nerve Connector: A porcine submucosa extracellular matrix (ECM) coaptation aid. Competitors include Integra LifeSciences and Stryker in the nerve repair market.
  • Axoguard Nerve Protector: A porcine submucosa ECM for protecting injured peripheral nerves and tendons. Competitors are companies with similar products in this tissue repair area.
  • Avive Soft Tissue Membrane: A human amniotic membrane used for soft tissue repair.

Market Dynamics

industry overview logo Industry Overview

The peripheral nerve repair market is growing due to increasing incidence of traumatic injuries, surgical procedures, and awareness of nerve repair options. It involves biologics, nerve conduits, and coaptation aids.

Positioning

Axogen is a key player in the nerve repair market, particularly known for its Avance Nerve Graft. Its competitive advantage lies in its specialized focus and established allograft processing capabilities.

Total Addressable Market (TAM)

TAM estimated to be over $2 billion for peripheral nerve repair market. Axogen is positioned to capture a significant portion through expanded offerings and clinical studies.

Upturn SWOT Analysis

Strengths

  • Specialized focus on peripheral nerve repair
  • Established allograft processing capabilities
  • Strong brand recognition for Avance Nerve Graft
  • Proprietary technologies

Weaknesses

  • Reliance on allograft availability
  • Relatively high product costs
  • Limited product diversification beyond nerve repair
  • History of fluctuating profitability

Opportunities

  • Expanding product portfolio to address unmet needs
  • Increasing market penetration through sales and marketing
  • Gaining regulatory approvals for new products
  • Expanding geographically

Threats

  • Competition from larger medical device companies
  • Potential disruptions in allograft supply
  • Pricing pressures from healthcare providers
  • Changes in regulatory landscape

Competitors and Market Share

competitor logo Key Competitors

  • INTEGRA
  • STRYKER

Competitive Landscape

Axogen's focus on nerve repair gives it an edge. Integra and Stryker offer a broader range of surgical products, leading to different priorities. Axogen needs to defend its allograft market share while innovating.

Growth Trajectory and Initiatives

Historical Growth: Axogen has demonstrated revenue growth historically, driven by increased adoption of its products and expansion into new markets.

Future Projections: Analyst projections generally expect continued revenue growth, driven by factors such as aging population, increasing trauma incidents, and demand for biologics-based solutions.

Recent Initiatives: Recent initiatives include expanded sales force, product development efforts, and clinical studies to support product adoption.

Summary

Axogen is a specialized regenerative medicine company focused on nerve repair with a strong position in the allograft market. Its strength lies in its proprietary technology and focused approach, but relies heavily on allograft supply. Future growth depends on product innovation and market expansion, but faces competition from larger players and potential disruptions in allograft supply chains.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company reports
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is based on available data and estimates, which are subject to change. It is not financial advice. Market share data is estimated and may not reflect precise figures.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Axogen Inc

Exchange NASDAQ
Headquaters Alachua, FL, United States
IPO Launch date 1990-03-27
President, CEO & Director Mr. Michael D. Dale
Sector Healthcare
Industry Medical Devices
Full time employees 451
Full time employees 451

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.